{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:09:56Z","timestamp":1791684596711,"version":"4.3.4"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The presence of anti-melanoma differentiation-associated gene 5 (MDA5) antibodies in dermatomyositis (DM) is associated with an increased risk of developing rapidly progressive interstitial lung disease (RP-ILD) and a poor prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We aimed to explore whether tofacitinib could improve the prognosis of Anti-MDA5 antibody positive DM-interstitial lung disease (ILD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources and Methods:<\/jats:title>\n                    <jats:p>Studies were included if they compared mortality rate and infection events in patients with anti-MDA5 antibody positive DM-associated ILD who were treated with or without tofacitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The systematic review and meta-analysis included a total of 148 patients from four cohort studies. Fifty-eight patients with anti-MDA5 antibody positive DM-ILD who received combined treatment-containing tofacitinib were enrolled in the experimental group. Additionally, 90 DM-ILD patients who did not receive tofacitinib-based therapy were included in the control group. The pooled risk ratio (RR) for all-cause mortality was 0.61 (95% CI, 0.41\u20130.91, p\u2009=\u20090.02) with I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090 indicating no heterogeneity among the included studies. For virus infection risk, the pooled RR was 1.92 (95% CI, 0.90\u20134.10, p\u2009=\u20090.09), while bacterial and fungal infection-associated RRs were found to be 1.29 (95% CI, 0.65\u20132.55, p\u2009=\u20090.47) and 1.15 (95% CI, 0.46\u20132.89, p\u2009=\u20090.77), respectively. There was no statistically significant difference in infection risk between the two groups, and no heterogeneity was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our findings suggest that tofacitinib may reduce the risk of all-cause mortality in patients with anti-MDA5 antibody-positive DM-ILD without an increased risk of additional infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>PROSPERO: CRD42023445427; https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17534666241294000","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T12:42:23Z","timestamp":1730378543000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["The efficacy and safety of tofacitinib in anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis associated interstitial lung disease: a systematic review and meta-analysis"],"prefix":"10.1177","volume":"18","author":[{"given":"Yanhong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Huai\u2019an Cancer Hospital, Huai\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyi","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wei","sequence":"additional","affiliation":[{"name":"Yizheng Center for Disease Prevention and Control, Yizheng, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Hospital of Zhuzhou, Zhuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-9475","authenticated-orcid":false,"given":"Minjie","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, No.1 Zhongfu Road, Gulou District, Nanjing 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"bibr1-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151959"},{"key":"bibr2-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21985"},{"key":"bibr3-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900045"},{"key":"bibr4-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1021\/jm801142b"},{"issue":"1","key":"bibr5-17534666241294000","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.gastrohep.2020.04.012","volume":"44","author":"Lopez-Sanroman A","year":"2021","journal-title":"Gastroent Hepat-Barc"},{"key":"bibr6-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0835-9"},{"key":"bibr7-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"bibr8-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1002\/path.4355"},{"key":"bibr9-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key341"},{"key":"bibr10-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06567-y"},{"key":"bibr11-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002795"},{"key":"bibr12-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.02.003"},{"key":"bibr13-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120621"},{"key":"bibr14-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"bibr15-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468"},{"key":"bibr16-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"bibr17-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"bibr18-17534666241294000","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220367"},{"issue":"2","key":"bibr19-17534666241294000","first-page":"291","volume":"41","author":"Shirai T","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"bibr20-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key188"},{"key":"bibr21-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24726"},{"key":"bibr22-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2018.08.007"},{"key":"bibr23-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1002\/art.34657"},{"key":"bibr24-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1111\/tan.13171"},{"key":"bibr25-17534666241294000","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170165"},{"key":"bibr26-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab371"},{"key":"bibr27-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"bibr28-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457"},{"issue":"2","key":"bibr29-17534666241294000","first-page":"84","volume":"9","author":"Louder AM","year":"2016","journal-title":"Am Health Drug Benef"},{"key":"bibr30-17534666241294000","doi-asserted-by":"publisher","DOI":"10.1002\/art.41602"},{"issue":"15","key":"bibr31-17534666241294000","volume":"101","author":"Chrong-Reen Wang MP","year":"2022","journal-title":"Medicine"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666241294000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666241294000","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666241294000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T15:46:51Z","timestamp":1740844011000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666241294000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"alternative-id":["10.1177\/17534666241294000"],"URL":"https:\/\/doi.org\/10.1177\/17534666241294000","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666241294000\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241294000\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241294000\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241294000\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241294000\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241294000\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241294000\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241294000\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241294000\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241294000\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666241294000\/v3\/decision1","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"17534666241294000"}}